Financings in Brief: Centocor Diagnostics
This article was originally published in The Gray Sheet
Centocor Diagnostics: Postpones initial public offering due to adverse market conditions. Parent firm Centocor, Inc. announced plans in October to spin-out shares in its Centocor Diagnostics subsidiary via an IPO of up to $40 mil. in Class A common stock ("The Gray Sheet" Oct. 27, I&W-3). Proceeds from the offering would go towards Centocor Diagnostics' cardiovascular diagnostic program, working capital, R&D and general corporate purposes. Morgan Stanley Dean Witter and Credit Suisse First Boston were to manage the offering...
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.